|

Zongertinib Clinical Trials

5 actively recruiting trials across 5 locations

Also known as: BI 1810631, Hernexeos®

Pipeline

Phase 1: 1Phase 2: 1Phase 3: 2Phase 1/2: 1

Top Sponsors

  • Boehringer Ingelheim5

Indications

  • Cancer5
  • Lung Cancer3
  • Non Small Cell Lung Cancer2
  • Lung Cancer, Non-squamous, Non-small Cell1
  • Metastatic Gastric Adenocarcinoma1

Birmingham, Alabama1 trial

Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

University of Alabama at Birmingham

Phase 1

Huntsville, Alabama1 trial

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

Clearview Cancer Institute

Phase 3

Anchorage, Alaska1 trial

Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations

Alaska Oncology and Hematology, LLC

Phase 2

Phoenix, Arizona1 trial

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Mayo Clinic-Arizona

Phase 1/2

Fresno, California1 trial

Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

ClinRé 001-022 (Premier Cancer Care and Infusion Center)

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.